Latest Bayer Inc. Stories
Bayer celebrates 150-year anniversary by honouring Canadians who have made a mark on society through science and innovation TORONTO, May 7, 2013 /CNW/ - Scientists and innovators have guided every step in Bayer's 150-year journey to becoming a global leader in healthcare, crop and material sciences. As it marks its 150(th) anniversary this year, Bayer also celebrates Canadian innovation and individuals who exemplify the curiosity and commitment to help shape a better future....
Stivarga(®) (Regorafenib tablets) demonstrated extended overall survival in patients with Metastatic Colorectal Cancer whose disease progressed after previous treatments TORONTO, March 25, 2013 /CNW/ - Bayer Inc. announced today the Health Canada approval of Stivarga (regorafenib tablets), indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an...
New CONTOUR(®) NEXT EZ Strip and Meter Combination is accurate and easy to use TORONTO, Jan. 9, 2013 /CNW/ - A new, accurate and easy-to-use blood glucose monitoring system is now available for diabetes patients in Canada. The CONTOUR(®) NEXT EZ meter combines easy-to-use features and next-generation accuracy with Bayer's new CONTOUR(®) NEXT test strip to help patients better manage their diabetes. "Bayer's new CONTOUR(®) NEXT EZ system is especially accurate in low blood...
Former fighter pilot, Jim "Murph" Murphy, delivered his nationally acclaimed Flawless Execution® model to more than 60 members of Bayer Healthcare Pharmaceuticals leadership team in Lisbon, Portugal Atlanta, GA (PRWEB) December 03, 2012 Jim Murphy, founder of the global management training firm, Afterburner, was featured as the guest speaker at Bayer Healthcare’s annual leadership meeting in Portugal this month. The concept behind Flawless Execution® combines...
-- First publication of the global Phase III CORRECT and GRID study data of the oral multi-kinase inhibitor regorafenib TORONTO, Nov. 27, 2012 /CNW/ - Bayer HealthCare today announced that the results of two pivotal Phase III studies for regorafenib were published online in the journal The Lancet ahead of a future print publication. Data from the CORRECT (Metastatic Colorectal cancer treated with regorafenib or placebo after failure of standard therapy)...
-- Coronary or Peripheral Artery Disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke -- Rivaroxaban is the first novel oral anticoagulant currently under investigation in this high risk patient population -- 20,000-patient study will be conducted in collaboration with Canada's Population Health Research Institute (PHRI), representing one of the largest...
Bayer Inc. welcomes support for public reimbursement of new treatment TORONTO, April 23, 2012 /PRNewswire/ - Hundreds of thousands of Canadians living with atrial fibrillation (AF) are now one step closer to getting public reimbursement for a new stroke prevention therapy - news that was welcomed today by Bayer Inc. The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR), has positively recommended to Canada's provincial and...
